[Additional experience with the beta blocker befunolol (Glaukonex) in open-angle glaucoma over a period of 1 year].
The results of a 3-month study of Befunolol eye drops 0.25% and 0.5% have already been published. The continuation of the study has shown that there is no diminution of the effect of the drug on IOP after a year of treatment. The absence of significant influences on pulse, systolic and diastolic blood pressure, corneal sensitivity, tear production, pupil diameter, visual acuity or visual field, which was established within the first 12 weeks, was also confirmed after 12 months.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D009883:Ophthalmic Solutions; D011412:Propanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D009883:Ophthalmic Solutions; D011412:Propanolamines; C006034:befunolol
Weitere Erfahrungen mit dem Beta-Blocker Befunolol (Glaukonex) bei Glaukomen mit weitem Kammerwinkel über einen Zeitraum von einem Jahr.